Skip to menu Skip to content Skip to footer
Dr Lauren Aoude
Dr

Lauren Aoude

Email: 
Phone: 
+61 7 344 38027

Overview

Background

Dr Lauren Aoude was awarded a PhD in melanoma genetics from the University of Queensland in 2014. Her research focused on large scale genetic sequencing projects that described novel melanoma predisposition genes. In 2016, Dr Aoude was awarded an NHMRC Early Career Fellowship to investigate precision medicine for the treatment of metastatic melanoma.

Currently, Dr Aoude is a UQ Amplify Fellow in the Surgical Oncology Group at the University of Queensland Diamantina Institute. Her research primarily focuses on ways to better predict treatment responses and outcomes for patients with cancer, particularly melanoma and oesophageal adenocarcinoma. Her research integrates genomic sequencing data from both tumours and circulating tumour DNA with clinical, pathological and imaging information. The results of her research will inform treatment decisions and improve health outcomes for patients through the integration of genomics into the clinic.

Availability

Dr Lauren Aoude is:
Available for supervision

Qualifications

  • Bachelor of Arts, The University of Queensland
  • Bachelor of Engineering, The University of Queensland
  • Doctor of Philosophy, The University of Queensland

Works

Search Professor Lauren Aoude’s works on UQ eSpace

46 works between 2008 and 2024

1 - 20 of 46 works

Featured

2022

Journal Article

ctDNA as a biomarker of progression in oesophageal adenocarcinoma

Bonazzi, V. F., Aoude, L. G., Brosda, S., Lonie, J. M., Patel, K., Bradford, J. J., Koufariotis, L. T., Wood, S., Smithers, B. Mark, Waddell, N. and Barbour, A. P. (2022). ctDNA as a biomarker of progression in oesophageal adenocarcinoma. ESMO Open, 7 (3) 100452, 100452. doi: 10.1016/j.esmoop.2022.100452

ctDNA as a biomarker of progression in oesophageal adenocarcinoma

Featured

2021

Journal Article

Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients

Aoude, Lauren G., Wong, Bernadette, Bonazzi, Vanessa F, Brosda, Sandra, Walters, Shaun B., Koufariotis, Lambros T., Naeini, Marjan M., Pearson, John V, Oey, Harald, Patel, Kalpana, Bradford, Julia J., Bloxham, Conor J, Atkinson, Victoria, Law, Phillip, Strutton, Geoffrey, Bayley, Gerard, Yang, Samuel, Smithers, B. Mark, Waddell, Nicola, Miles, Kenneth and Barbour, Andrew P. (2021). Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients. Molecular Cancer Research, 19 (6) molcanres.1038.2020, 950-956. doi: 10.1158/1541-7786.mcr-20-1038

Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients

Featured

2020

Journal Article

Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients

Aoude, Lauren G., Bonazzi, Vanessa F., Brosda, Sandra, Patel, Kalpana, Koufariotis, Lambros T., Oey, Harald, Nones, Katia, Wood, Scott, Pearson, John V., Lonie, James M., Arneil, Melissa, Atkinson, Victoria, Smithers, B. Mark, Waddell, Nicola and Barbour, Andrew P. (2020). Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports, 10 (1) 17687, 17687. doi: 10.1038/s41598-020-74956-3

Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients

2015

Journal Article

A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma

Wadt, K. A. W., Aoude, L. G., Johansson, P., Solinas, A., Pritchard, A., Crainic, O., Andersen, M. T., Kiilgaard, J. F., Heegaard, S., Sunde, L., Federspiel, B., Madore, J., Thompson, J. F., Mccarthy, S. W., Goodwin, A., Tsao, H., Jonsson, G., Busam, K., Gupta, R., Trent, J. M., Gerdes, A. -M., Brown, K. M., Scolyer, R. A. and Hayward, N. K. (2015). A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clinical Genetics, 88 (3), 267-272. doi: 10.1111/cge.12501

A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma

Featured

2015

Journal Article

POLE mutations in families predisposed to cutaneous melanoma

Aoude, Lauren G., Heitzer, Ellen, Johansson, Peter, Gartside, Michael, Wadt, Karin, Pritchard, Antonia L., Palmer, Jane M., Symmons, Judith, Gerdes, Anne-Marie, Montgomery, Grant W., Martin, Nicholas G., Tomlinson, Ian, Kearsey, Stephen and Hayward, Nicholas K. (2015). POLE mutations in families predisposed to cutaneous melanoma. Familial Cancer, 14 (4), 621-628. doi: 10.1007/s10689-015-9826-8

POLE mutations in families predisposed to cutaneous melanoma

2014

Journal Article

Assessment of PALB2 as a candidate melanoma susceptibility gene

Aoude, Lauren G., Xu, Mai, Zhao, Zhen Zhen, Kovacs, Michael, Palmer, Jane M., Johansson, Peter, Symmons, Judith, Trent, Jeffrey M., Martin, Nicholas G., Montgomery, Grant W., Brown, Kevin M. and Hayward, Nicholas K. (2014). Assessment of PALB2 as a candidate melanoma susceptibility gene. PLoS One, 9 (6) e100683, e100683.1-e100683.7. doi: 10.1371/journal.pone.0100683

Assessment of PALB2 as a candidate melanoma susceptibility gene

Featured

2013

Journal Article

A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers

Aoude, Lauren G., Wadt, Karin, Bojesen, Anders, Cruger, Dorthe, Borg, Ake, Trent, Jeffrey M., Brown, Kevin M., Gerdes, Anne-Marie, Jonsson, Goran and Hayward, Nicholas K. (2013). A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers. PloS One, 8 (8) e72144, e72144. doi: 10.1371/journal.pone.0072144

A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers

2024

Journal Article

Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy

Brosda, Sandra, Aoude, Lauren G., Bonazzi, Vanessa F., Patel, Kalpana, Lonie, James M., Belle, Clemence J., Newell, Felicity, Koufariotis, Lambros T., Addala, Venkateswar, Naeini, Marjan M., Simes, John, Walpole, Euan T., Mai, Gang T., Watson, David I., Karapetis, Chris S., Gebski, Val, Barnes, Elizabeth H., Oostendorp, Martijn, Wilson, Kate, Ackland, Stephen P., Shannon, Jenny, Marx, Gavin, Burge, Matthew, Finch, Robert, Thomas, Janine, Varma, Suresh, Nott, Louise, Pearson, John V., Krause, Lutz ... AGITG DOCTOR Investigators (2024). Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy. Genome Medicine, 16 (1) 90, 90. doi: 10.1186/s13073-024-01362-z

Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy

2024

Journal Article

POT1 and multiple primary melanomas: the dermatological phenotype

Maas, Ellie J., DeBortoli, Emily, Nathan, Vaishnavi, Freeman, Ned P., Mothershaw, Adam, Smit, Darren J., Betz-Stablein, Brigid, Aoude, Lauren G., Stark, Mitchell S., Sturm, Richard A., Soyer, H. Peter and McInerney-Leo, Aideen M. (2024). POT1 and multiple primary melanomas: the dermatological phenotype. Journal of Medical Genetics, 61 (9) jmg-2023-109637, 1-4. doi: 10.1136/jmg-2023-109637

POT1 and multiple primary melanomas: the dermatological phenotype

2024

Journal Article

The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective

Yee, Joshua, Rosendahl, Cliff and Aoude, Lauren G. (2024). The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective. Melanoma Research, 34 (2), 96-104. doi: 10.1097/cmr.0000000000000951

The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective

2023

Journal Article

The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank

Lonie, James M., Brosda, Sandra, Bonazzi, Vanessa F., Aoude, Lauren G., Patel, Kalpana, Brown, Ian, Sharma, Sowmya, Lampe, Guy, Addala, Venkateswar, Koufariotis, Lambros T., Wood, Scott, Waddell, Nicola, Dolcetti, Riccardo and Barbour, Andrew P. (2023). The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank. Frontiers in Immunology, 14 1220129, 1-15. doi: 10.3389/fimmu.2023.1220129

The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank

2023

Journal Article

ctDNA: a promising biomarker for predicting recurrence in BRAF-negative melanoma patients

Aoude, Lauren G., Brosda, Sandra, Ng, Jessica, Lonie, James M., Belle, Clemence J., Patel, Kalpana, Koufariotis, Lambros T., Wood, Scott, Atkinson, Victoria, Smithers, B. Mark, Pearson, John V., Waddell, Nicola, Barbour, Andrew P. and Bonazzi, Vanessa F. (2023). ctDNA: a promising biomarker for predicting recurrence in BRAF-negative melanoma patients. Journal of Molecular Diagnostics, 25 (10), 771-781. doi: 10.1016/j.jmoldx.2023.06.014

ctDNA: a promising biomarker for predicting recurrence in BRAF-negative melanoma patients

2023

Journal Article

GOLM1: expanding our understanding of melanoma susceptibility

Maas, Ellie J., Wallingford, Courtney K., DeBortoli, Emily, Smit, Darren J., Betz-Stablein, Brigid, Aoude, Lauren G., Stark, Mitchell S., Sturm, Richard A., Soyer, H. Peter and McInerney-Leo, Aideen M. (2023). GOLM1: expanding our understanding of melanoma susceptibility. Journal of Medical Genetics, 60 (9) jmg-2023-109348, 1-3. doi: 10.1136/jmg-2023-109348

GOLM1: expanding our understanding of melanoma susceptibility

2023

Journal Article

C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients

Bonazzi, Vanessa F., Aoude, Lauren G., Brosda, Sandra, Bradford, Julia J., Lonie, James M., Loffler, Kelly A., Gartside, Michael G., Patel, Kalpana, Mukhopadhyay, Pamela, Keane, Colm, Gebski, Val, Kench, James G., Goldstein, David, Waddell, Nicola, Barbour, Andrew P. and the Australasian Gastro‐Intestinal Trials Group (AGITG) GAP investigators (2023). C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients. Asia-Pacific Journal of Clinical Oncology. doi: 10.1111/ajco.13993

C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients

2023

Journal Article

Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy

M. Naeini, Marjan, Newell, Felicity, Aoude, Lauren G., Bonazzi, Vanessa F., Patel, Kalpana, Lampe, Guy, Koufariotis, Lambros T., Lakis, Vanessa, Addala, Venkateswar, Kondrashova, Olga, Johnston, Rebecca L., Sharma, Sowmya, Brosda, Sandra, Holmes, Oliver, Leonard, Conrad, Wood, Scott, Xu, Qinying, Thomas, Janine, Walpole, Euan, Tao Mai, G., Ackland, Stephen P., Martin, Jarad, Burge, Matthew, Finch, Robert, Karapetis, Christos S., Shannon, Jenny, Nott, Louise, Bohmer, Robert, Wilson, Kate ... Waddell, Nicola (2023). Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy. Nature Communications, 14 (1) 3155, 3155. doi: 10.1038/s41467-023-38891-x

Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy

2023

Conference Publication

Unusual suspects in hereditary melanoma: POT1, POLE and BAP1

Maas, Ellie, Betz-Stablein, Brigid, Aoude, Lauren, Soyer, Hans Peter and McInerney-Leo, Aideen (2023). Unusual suspects in hereditary melanoma: POT1, POLE and BAP1. 55th European Society of Human Genetics (ESHG) Conference, Vienna, Austria, 11-14 June 2022. London, United Kingdom: Nature Publishing Group.

Unusual suspects in hereditary melanoma: POT1, POLE and BAP1

2022

Journal Article

Unusual suspects in hereditary melanoma: POT1, POLE, BAP1

Maas, Ellie J., Betz-Stablein, Brigid, Aoude, Lauren G., Soyer, H. Peter and McInerney-Leo, Aideen M. (2022). Unusual suspects in hereditary melanoma: POT1, POLE, BAP1. Trends in Genetics, 38 (12), 1204-1207. doi: 10.1016/j.tig.2022.06.007

Unusual suspects in hereditary melanoma: POT1, POLE, BAP1

2022

Conference Publication

Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma

Aoude, L.G., Bonazzi, V.F., Brosda, S., Wong, B., Moradi, H., Lonie, J., Bradford, J., Bloxham, C., Atkinson, V.G., Law, P., Lampe, G., Smithers, M., Waddell, N., Vegh, V., Miles, K. and Barbour, A.P. (2022). Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma. ESMO Congress 2022, Singapore, 9 - 13 September 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.07.1357

Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma

2022

Journal Article

Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels

Ramarao-Milne, P, Kondrashova, O, Patch, A-M, Nones, K, Koufariotis, L T, Newell, F, Addala, V, Lakis, V, Holmes, O, Leonard, C, Wood, S, Xu, Q, Mukhopadhyay, P, Naeini, M M, Steinfort, D, Williamson, J P, Bint, M, Pahoff, C, Nguyen, P T, Twaddell, S, Arnold, D, Grainge, C, Basirzadeh, F, Fielding, D, Dalley, A J, Chittoory, H, Simpson, P T, Aoude, L G, Bonazzi, V F ... Waddell, N (2022). Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels. ESMO Open, 7 (4) 100540, 1-11. doi: 10.1016/j.esmoop.2022.100540

Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels

2022

Conference Publication

Classification of esophageal adenocarcinoma into subgroups that are associated with patient survival using RNA-seq and immunohistochemistry

Sharma, Sowmya, Naeini, Marjan, Aoude, Lauren G., Bonazzi, Vanessa F., Gartside, Michael G., Loffler, Kelly A., Patel, Kalpana, Newell, Felicity, Lampe, Guy, Brosda, Sandra, Thomas, Janine, Smithers, Mark, Simes, John, Watson, David I., Pearson, John, Barbour, Andrew and Waddell, Nic (2022). Classification of esophageal adenocarcinoma into subgroups that are associated with patient survival using RNA-seq and immunohistochemistry. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Classification of esophageal adenocarcinoma into subgroups that are associated with patient survival using RNA-seq and immunohistochemistry

Funding

Current funding

  • 2025 - 2029
    Enabling precision medicine for oesophageal cancer patients
    NHMRC Investigator Grants
    Open grant
  • 2023 - 2025
    Radiomics analysis to improve outcomes for melanoma patients (Cancer Australia via the Priority-driven Collaborative Cancer Research Scheme (PdCCRS))
    Cancer Australia
    Open grant
  • 2023 - 2026
    Assessment of tumour phenotype for precision medicine in oesophageal cancer via deep learning analysis of medical images
    CCQ Accelerating Collaborative Cancer Research
    Open grant
  • 2022 - 2024
    Investigating tumour evolution to improve precision medicine in patients with oesophageal adenocarcinoma (MSH RSS Project Grant led by Metro South Health)
    Metro South Hospital and Health Service
    Open grant
  • 2020 - 2025
    Improving outcomes for patients with melanoma brain metastases
    Community Skilling & Disability Support Service Inc (trading name: Civic Solutions)
    Open grant

Past funding

  • 2020 - 2021
    Cancer Evolution Biobank
    PA Research Foundation
    Open grant
  • 2019 - 2021
    Tumour neo-antigen-specific immune responses in oesophageal cancer long-term survivors: proof-of-concept for improved personalised therapeutic strategies
    Metro South Hospital and Health Service
    Open grant
  • 2018 - 2019
    Genomics and biological correlates of radiomics in melanoma (Cancer Australia administered project funded by Cure Cancer Australia)
    Cure Cancer Australia Foundation
    Open grant
  • 2017 - 2018
    Dr Lauren Aoude - Maternity Funding (Advance Queensland Women's Academic Fund)
    Queensland Government Advance Queensland Women's Academic Fund
    Open grant
  • 2016 - 2021
    Feasibility of implementing precision medicine for the treatment of metastatic melanoma
    NHMRC Early Career Fellowships
    Open grant

Supervision

Availability

Dr Lauren Aoude is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Media

Enquiries

For media enquiries about Dr Lauren Aoude's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au